ADVANCED NON-SMALL-CELL LUNG CANCER. THE SIGNIFICANCE OF PERSONALIZED THERAPY
نویسندگان
چکیده
منابع مشابه
Personalized Combined Modality Therapy for Locally Advanced Non-small Cell Lung Cancer
Locally advanced non-small cell lung cancer (NSCLC) is a heterogeneous disease, and we have embarked on an era where patients will benefit from individualized therapeutic strategies based on identifiable molecular characteristics of the tumor. The landmark studies demonstrating the importance of molecular characterization of tumors for NSCLC patients, the promising molecular pathways, and the p...
متن کاملThird-line therapy in advanced non-small cell lung cancer.
PURPOSE With the improvements in first- and second-line treatments in non-small cell lung cancer (NSCLC), there is an increasing number of patients who receive third-line therapy. No other standard choice for third-line therapy aside from erlotinib is possible. This study investigated the efficacy and safety of single-agent chemotherapy, epidermal growth factor receptor-tyrosine kinase inhibito...
متن کامل[Consolidation therapy in advanced non-small cell lung cancer].
Standard management of advanced non-small cell lung cancer includes palliative chemotherapy, but its efficacy is modest. In most cases a few cycles of palliative chemotherapy are administered, as there is no evidence of benefit associated with prolonged treatment. Recently, there is an interest in a new approach including treatment continuation using cytotoxic compounds of proved efficacy in se...
متن کامل[Maintenance therapy for advanced non-small-cell lung cancer].
Maintenance therapy is a new treatment strategy for advanced non-small-cell lung cancer(NSCLC), and it consists of switch maintenance and continuation maintenance.Switch maintenance is the introduction of a different drug, not included as part of the induction therapy, immediately after completion of 4 cycles of first-line platinum-based chemotherapy.Continuation maintenance is a continuation o...
متن کاملAntiangiogenesis for Advanced Non-Small-Cell Lung Cancer in the Era of Immunotherapy and Personalized Medicine
Over the past decade, patients with advanced non-small-cell lung cancer (NSCLC) have witnessed substantial advances in regards to therapeutic alternatives. Among newly developed agents, angiogenesis inhibitors were extensively tested in different settings and have produced some favorable outcomes despite several shortcomings. Bevacizumab is the most examined agent in this context and has demons...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Siberian Medical Review
سال: 2017
ISSN: 1819-9496,2500-0136
DOI: 10.20333/2500136-2017-6-12